
Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Drugs In Development, 2022, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 7, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Drugs In Development, 2022, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 7, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
90 Pages
- Introduction
- Global Markets Direct Report Coverage
- Hyperuricemia – Overview
- Hyperuricemia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperuricemia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperuricemia – Companies Involved in Therapeutics Development
- Allena Pharmaceuticals Inc
- Amendment Biomedical (Hangzhou) Research Institute Co Ltd
- Arthrosi Therapeutics Inc
- AstraZeneca Plc
- Evopoint Bioscience Co Ltd
- Fochon Pharmaceutical Ltd
- FortuneRock (China) Ltd
- Fuji Yakuhin Co Ltd
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Hangzhou Grand Biologic Pharmaceutical Inc
- Hinova Pharmaceuticals Co Ltd
- InventisBio Inc
- J-Pharma Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Nippon Chemiphar Co Ltd
- NuBioPharma LLC
- PegBio Co Ltd
- Shanghai Institute of Biological Products Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shanton Pharma Co Ltd
- Stealth Biologics LLC
- Teijin Pharma Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- Waterstone Pharmaceuticals (Wuhan) Ltd
- Hyperuricemia – Drug Profiles
- (allopurinol +verinurad) – Drug Profile
- ABP-671 – Drug Profile
- ALLN-346 – Drug Profile
- allopurinol – Drug Profile
- AR-882 – Drug Profile
- D-0120 – Drug Profile
- FCN-207 – Drug Profile
- febuxostat – Drug Profile
- HEC-93077 – Drug Profile
- HP-501 SR – Drug Profile
- HZBio-1 – Drug Profile
- JPH-367 – Drug Profile
- JS-103 – Drug Profile
- NC-2500 – Drug Profile
- NC-2700 – Drug Profile
- PB-348 – Drug Profile
- Peguricase – Drug Profile
- PEGylated uricase – Drug Profile
- Recombinant Enzyme for Gout and Hyperuricemia – Drug Profile
- SAP-001 – Drug Profile
- SFR-9350 – Drug Profile
- SHR-4640 – Drug Profile
- Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile
- Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
- Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
- taininade – Drug Profile
- THDBH-130 – Drug Profile
- THDBH-131 – Drug Profile
- THDBH-150 – Drug Profile
- THDBH-151 – Drug Profile
- TMX-049 – Drug Profile
- topiroxostat – Drug Profile
- WS-015 – Drug Profile
- XNW-3009 – Drug Profile
- YL-90148 – Drug Profile
- Hyperuricemia – Dormant Projects
- Hyperuricemia – Discontinued Products
- Hyperuricemia – Product Development Milestones
- Featured News & Press Releases
- Nov 03, 2021: Allena Pharmaceuticals receives Fast Track Designation from FDA for the Development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease
- Jul 12, 2021: Allena Pharmaceuticals provides update on ALLN-346 clinical development program
- Mar 05, 2021: Shanghai Junshi Bioscience announces JS103 Injection received the acceptance notice for the investigational new drug application
- Nov 30, 2020: Allena Pharmaceuticals announces initial data from phase 1 trial of ALLN-346
- Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of Hyperuricemia in patients with gout and advanced chronic kidney disease
- Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
- Aug 01, 2019: HP501 has launched Phase I clinical trial
- Aug 01, 2019: HP501 China Phase I clinical trial first participants enrolled
- Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
- Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
- Jun 19, 2019: HP501 announces Phase I trial update
- Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
- Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
- Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
- Aug 31, 2018: Haichuang Pharmaceutical High-uricemia and Gout New Drugs Receive CFDA Drug Registration
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Hyperuricemia, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Universities/Institutes, 2022
- Table 8: Number of Products by Stage and Target, 2022
- Table 9: Number of Products by Stage and Mechanism of Action, 2022
- Table 10: Number of Products by Stage and Route of Administration, 2022
- Table 11: Number of Products by Stage and Molecule Type, 2022
- Table 12: Hyperuricemia – Pipeline by Allena Pharmaceuticals Inc, 2022
- Table 13: Hyperuricemia – Pipeline by Amendment Biomedical (Hangzhou) Research Institute Co Ltd, 2022
- Table 14: Hyperuricemia – Pipeline by Arthrosi Therapeutics Inc, 2022
- Table 15: Hyperuricemia – Pipeline by AstraZeneca Plc, 2022
- Table 16: Hyperuricemia – Pipeline by Evopoint Bioscience Co Ltd, 2022
- Table 17: Hyperuricemia – Pipeline by Fochon Pharmaceutical Ltd, 2022
- Table 18: Hyperuricemia – Pipeline by FortuneRock (China) Ltd, 2022
- Table 19: Hyperuricemia – Pipeline by Fuji Yakuhin Co Ltd, 2022
- Table 20: Hyperuricemia – Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022
- Table 21: Hyperuricemia – Pipeline by Hangzhou Grand Biologic Pharmaceutical Inc, 2022
- Table 22: Hyperuricemia – Pipeline by Hinova Pharmaceuticals Co Ltd, 2022
- Table 23: Hyperuricemia – Pipeline by InventisBio Inc, 2022
- Table 24: Hyperuricemia – Pipeline by J-Pharma Co Ltd, 2022
- Table 25: Hyperuricemia – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2022
- Table 26: Hyperuricemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 27: Hyperuricemia – Pipeline by Nippon Chemiphar Co Ltd, 2022
- Table 28: Hyperuricemia – Pipeline by NuBioPharma LLC, 2022
- Table 29: Hyperuricemia – Pipeline by PegBio Co Ltd, 2022
- Table 30: Hyperuricemia – Pipeline by Shanghai Institute of Biological Products Co Ltd, 2022
- Table 31: Hyperuricemia – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 32: Hyperuricemia – Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, 2022
- Table 33: Hyperuricemia – Pipeline by Shanton Pharma Co Ltd, 2022
- Table 34: Hyperuricemia – Pipeline by Stealth Biologics LLC, 2022
- Table 35: Hyperuricemia – Pipeline by Teijin Pharma Ltd, 2022
- Table 36: Hyperuricemia – Pipeline by Tonghua Dongbao Pharmaceutical Co Ltd, 2022
- Table 37: Hyperuricemia – Pipeline by Waterstone Pharmaceuticals (Wuhan) Ltd, 2022
- Table 38: Hyperuricemia – Dormant Projects, 2022
- Table 39: Hyperuricemia – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Hyperuricemia, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Targets, 2022
- Figure 5: Number of Products by Stage and Targets, 2022
- Figure 6: Number of Products by Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.